Skip to content
10-Q

Quarterly Report

ACADIA PHARMACEUTICALS INC ACAD

0001193125-26-209731

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 29, 2026 171.24M sh
Shares Diluted Q1 2026 · Mar 31, 2026 172.71M sh
Shares Diluted Q1 2026 · Mar 31, 2025 167.67M sh
Capex Q1 2026 · Mar 31, 2026 $5.21M
Capex Q1 2026 · Mar 31, 2025 $0
Operating Cash Flow Q1 2026 · Mar 31, 2026 $33.98M
Operating Cash Flow Q1 2026 · Mar 31, 2025 $20.32M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $282.21M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $177.7M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $217.7M
Cash And Equivalents Q1 2026 · Dec 31, 2024 $319.59M
Stockholders Equity Q1 2026 · Mar 31, 2026 $1.25B
Stockholders Equity Q1 2026 · Dec 31, 2025 $1.23B
Stockholders Equity Q1 2026 · Mar 31, 2025 $765.24M
Stockholders Equity Q1 2026 · Dec 31, 2024 $732.79M
Current Liabilities Q1 2026 · Mar 31, 2026 $305.52M
Current Liabilities Q1 2026 · Dec 31, 2025 $277.11M
Total Liabilities Q1 2026 · Mar 31, 2026 $357.16M
Total Liabilities Q1 2026 · Dec 31, 2025 $336.81M
Current Assets Q1 2026 · Mar 31, 2026 $1.1B
Current Assets Q1 2026 · Dec 31, 2025 $1.06B
Total Assets Q1 2026 · Mar 31, 2026 $1.61B
Total Assets Q1 2026 · Dec 31, 2025 $1.56B
Eps Diluted Q1 2026 · Mar 31, 2026 $0.02
Eps Diluted Q1 2026 · Mar 31, 2025 $0.11
Eps Basic Q1 2026 · Mar 31, 2026 $0.02
Eps Basic Q1 2026 · Mar 31, 2025 $0.11
Sga Expense Q1 2026 · Mar 31, 2026 $171.02M
Sga Expense Q1 2026 · Mar 31, 2025 $126.37M
Rd Expense Q1 2026 · Mar 31, 2026 $76.87M
Rd Expense Q1 2026 · Mar 31, 2025 $78.27M
Net Income Q1 2026 · Mar 31, 2026 $3.64M
Net Income Q1 2026 · Mar 31, 2025 $18.99M
Operating Income Q1 2026 · Mar 31, 2026 −$4.62M
Operating Income Q1 2026 · Mar 31, 2025 $19.29M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $24.79M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $20.39M
Revenue Q1 2026 · Mar 31, 2026 $268.06M
Revenue Q1 2026 · Mar 31, 2025 $244.32M